

Accepted Manuscript

Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology

Glyn Taylor, Simon Warren, Sarvajna Dwivedi, Mark Sommerville, Lauren Mello, Chad Orevillo, Andrea Maes, Ubaldo J. Martin, Omar S. Usmani



PII: S0928-0987(17)30581-X

DOI: doi:[10.1016/j.ejps.2017.10.026](https://doi.org/10.1016/j.ejps.2017.10.026)

Reference: PHASCI 4272

To appear in: *European Journal of Pharmaceutical Sciences*

Received date: 23 June 2017

Revised date: 27 September 2017

Accepted date: 18 October 2017

Please cite this article as: Glyn Taylor, Simon Warren, Sarvajna Dwivedi, Mark Sommerville, Lauren Mello, Chad Orevillo, Andrea Maes, Ubaldo J. Martin, Omar S. Usmani, Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Phasci(2017), doi:[10.1016/j.ejps.2017.10.026](https://doi.org/10.1016/j.ejps.2017.10.026)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Gamma scintigraphic pulmonary deposition study of
glycopyrronium/formoterol metered dose inhaler formulated using
co-suspension delivery technology**

Glyn Taylor^a, Simon Warren^a, Sarvajna Dwivedi^{b*}, Mark Sommerville^c, Lauren Mello^c,
Chad Orevillo^d, Andrea Maes^e, Ubaldo J Martin^f, Omar S Usmani^g

^a*Cardiff Scintigraphics Ltd., Cardiff, UK*

^b*Pearl Therapeutics, Inc., Redwood City, CA, USA*

^c*Pearl Therapeutics Inc., Durham, NC, USA*

^d*Former employee of Pearl Therapeutics Inc., Morristown, NJ, USA*

^e*Pearl Therapeutics Inc., Morristown, NJ, USA*

^f*AstraZeneca, Gaithersburg, MD, USA*

^g*National Heart and Lung Institute (NHLI), Imperial College London, and Royal Brompton
Hospital, London, UK*

*Corresponding author at:

Pearl Therapeutics, Inc
200 Cardinal Way
Redwood City, CA 94063
USA

Tel: 001 650 339 2628

sdwivedi@pearltherapeutics.com

Download English Version:

<https://daneshyari.com/en/article/8512032>

Download Persian Version:

<https://daneshyari.com/article/8512032>

[Daneshyari.com](https://daneshyari.com)